文献速递肿瘤 PET/CT

18F-FDG PET/CT影像生物标志物早期与晚期评估胰腺导管腺癌一线化疗反应

18F-FDG PET/CT Imaging Biomarkers for Early and Late Evaluation of Response to First-Line Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma.
PubMed 文献 · J Nucl Med · 2021-07-16

前瞻性单中心单臂开放标签研究纳入28例接受一线化疗的胰腺导管腺癌患者,分别于基线、早期中期和晚期中期行18F-FDG PET/CT,采用改良PERCIST/RECIST1.1标准评估代谢与影像学反应并随访总生存。早期代谢反应者中位总生存36.2个月(P=0.016),晚期影像学反应者58.2个月(P=0.008)。结论提示18F-FDG PET可作为约4周时早期中期影像生物标志物评估一线化疗反应,而影像学变化可能足以在一线化疗完成后评估反应。

要点

  • 早期代谢反应与更长总生存相关(36.2个月,P=0.016)。
  • 晚期影像学反应与更长总生存相关(58.2个月,P=0.008)。
  • 18F-FDG PET或可于约4周时早期评估一线化疗反应。

核心结论

  • 18F-FDG PET可作为约4周时早期中期影像生物标志物评估胰腺导管腺癌一线化疗反应。
  • 一线化疗完成后影像学变化可能足以用于反应评估。

研究设计与样本

  • 前瞻性、单中心、单臂、开放标签研究(IRB12-000770)。
  • 接受一线化疗患者计划行基线、早期中期和晚期中期18F-FDG PET/CT。
  • 研究人群为28例接受基线18F-FDG PET/CT的患者,23例(82%)行早期中期PET/CT,21例(75%)行晚期中期PET/CT。
  • 采用受试者工作特征分析选定并建立的代谢与影像学肿瘤反应截断值(改良PERCIST/RECIST1.1)。
  • 随访收集中位14个月(最长随访58.3个月)内的后续治疗与总生存数据。

主要发现

  • 随访期间共23例死亡。
  • 早期代谢反应者6/23(26%),中位总生存36.2个月(95%CI 28个月至未达到),P=0.016。
  • 早期影像学反应者7/23(30%),中位总生存25.4个月(95%CI 19.6个月至未达到),P=0.16。
  • 晚期代谢反应者10/21(48%),中位总生存27.4个月(95%CI 21.4个月至未达到),P=0.058。
  • 晚期影像学反应者7/21(33%),中位总生存58.2个月(95%CI 21.4个月至未达到),P=0.008。

关键数值与推荐

  • 代谢与影像学肿瘤反应评估截断值由受试者工作特征分析选定并建立,采用改良PERCIST/RECIST1.1标准。

临床怎么用

  • 可考虑在约4周时行18F-FDG PET/CT早期中期评估一线化疗代谢反应。
  • 一线化疗完成后可依据影像学变化评估反应。

局限性

  • 单中心、单臂、开放标签研究,样本量有限(基线28例,早期中期23例,晚期中期21例)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The purpose of this study was to evaluate 18F-FDG PET/CT as an early and late interim imaging biomarker in patients with pancreatic ductal adenocarcinoma who undergo first-line systemic therapy. Methods: This was a prospective, single-center, single-arm, open-label study (IRB12-000770). Patient receiving first-line chemotherapy were planned to undergo baseline 18F-FDG PET/CT, early interim 18F-FDG PET/CT, and late interim 18F-FDG PET/CT. Cutoffs for metabolic and radiographic tumor response assessment as selected and established by receiver-operating-characteristic analysis were applied (modified PERCIST/RECIST1.1). Patients were followed to collect data on further treatments and overall survival. Results: The study population consisted of 28 patients who underwent baseline 18F-FDG PET/CT. Twenty-three of these (82%) underwent early interim 18F-FDG PET/CT, and 21 (75%) underwent late interim 18F-FDG PET/CT. Twenty-three deaths occurred during a median follow-up period of 14 mo (maximum follow-up, 58.3 mo). The median overall survival was 36.2 mo (95% CI, 28 mo to not yet reached [NYR]) in early metabolic responders (6/23 [26%], P = 0.016) and 25.4 mo (95% CI, 19.6 mo-NYR) in early radiographic responders (7/23 [30%], P = 0.16). The median overall survival was 27.4 mo (95% CI, 21.4 mo-NYR) in late metabolic responders (10/21 [48%], P = 0.058) and 58.2 mo (95% CI, 21.4 mo-NYR) in late radiographic responders (7/21 [33%], P = 0.008). Conclusion: 18F-FDG PET may serve as an early interim imaging biomarker (at ∼4 wk) for evaluation of response to first-line chemotherapy in patients with pancreatic ductal adenocarcinoma. Radiographic changes might be sufficient for response evaluation after the completion of first-line chemotherapy.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Benz MR, Armstrong WR, Ceci F, et al. 18F-FDG PET/CT Imaging Biomarkers for Early and Late Evaluation of Response to First-Line Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma. J Nucl Med. 2021. PMID: 34272317. doi:10.2967/jnumed.121.261952

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。